Key facts
- Direct Biologics’s last known valuation is $675.0M (Feb 2023).
- It has raised $3.5M across 1 recorded rounds; the latest was Early Stage VC ($11.6M) in Oct 2022.
- Notable investors include Granite Oak Capital, IB Investments, Tranquillion.
- Direct Biologics has filed 1 Form D with the SEC, most recently Dec 2022 ($11.6M sold to 116 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Direct Biologics
Funding rounds
1 roundsAbout Direct Biologics
Developer of regenerative therapies designed for developing Extracellular Vesicle products derived from adult human mesenchymal stem/stromal cells. The company's technology contains bioactive molecules with clinical therapeutic potential that are processed under controlled, specified, and validated current conditions that are compliant with the quality standards and stimulate a wide array of regulatory proteins to modulate within the normal healing cascade, enabling patients to have access to healing through advanced repairment and reconstruction of their tissue.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 49
- Website
- directbiologics.com/
- Ownership
- Privately Held (backing)
Direct Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Direct Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Direct Biologics in its N-PORT filings yet. We sweep new filings monthly.